Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Authors
Keywords
-
Journal
CELL RESEARCH
Volume 29, Issue 8, Pages 609-627
Publisher
Springer Science and Business Media LLC
Online
2019-07-02
DOI
10.1038/s41422-019-0184-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2019) Miguel F. Sanmamed et al. CELL
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
- (2018) Xuexiang Du et al. CELL RESEARCH
- A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
- (2018) Xuexiang Du et al. CELL RESEARCH
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rheumatic immune-related adverse events from cancer immunotherapy
- (2018) Leonard H. Calabrese et al. Nature Reviews Rheumatology
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- (2018) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Probe for the measurement of cell surface pH in vivo and ex vivo
- (2016) Michael Anderson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- (2015) Michele Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
- (2015) Michal Pyzik et al. JOURNAL OF IMMUNOLOGY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
- (2015) B. Lo et al. SCIENCE
- Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
- (2014) Ahmad A. Tarhini et al. PLoS One
- Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
- (2014) H. S. Kuehn et al. SCIENCE
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
- (2010) Tomoyuki Igawa et al. NATURE BIOTECHNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now